Biotech News

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics (CADL)Candel Therapeutics2026-06-25 13:46 ESTFinancing

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten

Open original release

Related news

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics to Present at Upcoming Investor Conferences

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Announces Pricing of Public Offering

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

View all latest news

Candel Therapeutics

Candel Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-06-26 08:45 EST

Candel Therapeutics to Present at Upcoming Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States